Edinburgh Research Explorer

Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers

Research output: Contribution to journalArticle

  • Antonia E Schantl
  • Anja Verhulst
  • Ellen Neven
  • Geert Behets
  • Patrick C. D'haese
  • Marc Maillard
  • DAvid Mordasini
  • Oliver Phan
  • Michel Burnier
  • Dany Spaggiari
  • Laurent A Decosterd
  • Carlos Alcaide Corral
  • Victoria C Beindl
  • Roberto Maj
  • Anne Labarre
  • Chrismita Hedge
  • Bastien Castagner
  • Mattias E Ivarsson
  • Jean-Christophe Leroux

Related Edinburgh Organisations

Open Access permissions

Open

Documents

  • Download as Adobe PDF

    Final published version, 2.65 MB, PDF document

Original languageEnglish
Article number721
JournalNature Communications
Volume11
DOIs
Publication statusPublished - 5 Feb 2020

Abstract

Myo-inositol hexakisphosphate (IP6) is a natural product known to inhibit vascular calcification (VC), but with limited potency and low plasma exposure following bolus administration. Here we report the design of a series of inositol phosphate analogs as crystallization inhibitors, among which 4,6-di-O-(methoxy-diethyleneglycol)-myo-inositol-1,2,3,5-tetrakis(phosphate), (OEG2)2-IP4, displays increased in vitro activity, as well as more favorable pharmacokinetic and safety profiles than IP6 after subcutaneous injection. (OEG2)2-IP4 potently stabilizes calciprotein particle (CPP) growth, consistently demonstrates low micromolar activity in different in vitro models of VC (i.e., human serum, primary cell cultures, and tissue explants), and largely abolishes the development of VC in rodent models, while not causing toxicity related to serum calcium chelation. The data suggest a mechanism of action independent of the etiology of VC, whereby (OEG2)2-IP4 disrupts the nucleation and growth of pathological calcification.

ID: 132374647